Search for:

Gene therapy vs cell therapy: Key differences

9 Mins Read

Medically reviewed by:

Gene therapy vs cell therapy

Two of the most transformative fields in modern medicine are advancing faster than most people realize, and they are easy to confuse. Gene therapy and cell therapy both aim to treat disease at its biological source rather than simply managing symptoms. But the way they work, the conditions they target, and the risks they carry differ in fundamental ways. For anyone navigating a diagnosis, following medical news, or simply trying to understand where medicine is heading, knowing this distinction is genuinely useful.

» GROUNDBREAKING: Japan approves first iPSC stem cell therapies

Gene therapy: Rewriting the body’s biological instructions

Gene therapy works by intervening at the level of DNA, the fundamental instruction code that tells your cells how to function. When a gene is faulty, missing, or overactive, it can cause disease. Gene therapy aims to correct that problem directly, rather than compensating for it with lifelong medication.

There are several approaches. A corrected copy of a faulty gene can be delivered into a patient’s cells to restore normal function. A harmful gene can be silenced so it no longer produces the damaging protein it was making. In newer approaches using CRISPR-based technology, specific sections of DNA can be precisely edited, added, removed, or changed, with a level of accuracy that was unimaginable twenty years ago. The most common delivery method uses modified viruses, called vectors, which are stripped of their ability to cause infection but retain the ability to enter cells and deposit genetic material. Adeno-associated viruses (AAVs) are the most widely used and have a relatively well-established safety profile.

The diseases most suited to gene therapy are those caused by a single identifiable genetic fault, so-called monogenic disorders. Spinal muscular atrophy (SMA), hemophilia B, certain inherited forms of blindness, and sickle cell disease are among the conditions where gene therapy has moved from clinical trials into approved treatments. Lyfgenia received FDA approval in December 2023 as an autologous cell-based gene therapy for patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events, with 88% of patients achieving complete resolution of such events in clinical trials.

The promise and the limits of genetic correction

The theoretical appeal of gene therapy is profound: treat the cause once, and potentially cure a disease for life. In practice, the picture is more complex. Long-term durability of effect is still being established in many conditions, as regulatory agencies typically require up to fifteen years of follow-up data after treatment. Immune reactions to viral vectors remain a monitored risk. And the cost of these therapies is extraordinary, some approved gene therapies carry price tags between one and four million dollars per patient, raising serious questions about equitable access that the medical community has not yet resolved.

The FDA currently requires 15 years of long-term follow-up after gene therapy administration to monitor for delayed effects including secondary malignancy, infection susceptibility, and off-target genetic changes. That requirement reflects both the genuine promise of these treatments and the honest acknowledgment that their long-term behavior in the human body is still being learned.

» READ MORE: Why your fat cells remember obesity

Cell therapy: Treating disease with living biological material

Cell therapy takes a different route. Rather than altering the genetic blueprint inside a patient’s existing cells, it introduces living cells, either from the patient themselves or from a donor — that perform a therapeutic function directly. Those cells may repair damaged tissue, replace cells that are missing or dysfunctional, or modulate the immune system’s response.

The oldest and most established form of cell therapy is the bone marrow transplant, used for decades in the treatment of leukemia, lymphoma, and other blood cancers. Here, diseased blood-forming stem cells are replaced by healthy donor cells that rebuild a functioning immune and blood system from scratch. This is a well-understood and life-saving procedure, though it carries significant risks including graft-versus-host disease when donor and recipient are not well-matched.

More recent advances have pushed cell therapy into new territory. Mesenchymal stem cells (MSCs), a type of adult stem cell found in bone marrow, fat tissue, and other sites, are being studied for their ability to reduce inflammation and support tissue regeneration in conditions ranging from osteoarthritis to autoimmune disease. Ryoncil received FDA approval in December 2024 as the first MSC therapy approved for pediatric steroid-refractory acute graft-versus-host disease, a life-threatening complication of bone marrow transplantation, representing a landmark in cell-based treatment.

CAR-T cell therapy has attracted particular attention in oncology. In this approach, a patient’s own T cells, a type of immune cell, are extracted, genetically modified in a laboratory to recognize cancer-specific proteins, and then reinfused in large numbers. The result is an immune army precisely engineered to hunt and destroy cancer cells. In 2024, Iovance’s Amtagvi became the first approved cell therapy for solid tumors, and Adaptimmune’s Tecelra became the first FDA-approved engineered T cell receptor therapy, both representing meaningful expansions of cell therapy beyond blood cancers where it had previously been concentrated.

Where gene and cell therapy overlap

The boundary between these two fields is becoming increasingly blurred, and that is not a problem, it reflects scientific maturation. CAR-T therapy is simultaneously a cell therapy and a gene therapy: living immune cells are collected from a patient, their genes are modified outside the body using gene editing tools, and the enhanced cells are returned. Casgevy, the world’s first CRISPR-based editing product, received expanded FDA approval in early 2024 for beta-thalassemia, and its mechanism combines genetic correction with cell-based delivery in a way that defies simple categorization. This convergence is not accidental, it reflects that the most effective treatments often need to address both the cell and its genetic programming simultaneously.

The bigger picture: Where are these fields heading?

The pace of regulatory approval in this space is accelerating meaningfully. In 2024, there were eight novel cell and gene therapy approvals and at least six new indications approved for existing therapies, an increase from prior years, with the FDA projecting approvals of 10 to 20 such therapies annually. As of early 2025, more than 2,500 active investigational applications for cell and gene therapies are on file with the FDA, signaling a pipeline that is broad and deepening.

That momentum comes with honest caveats. Several approved gene therapies, including Pfizer’s Beqvez for hemophilia B, have been discontinued not because of safety failures, but because commercial uptake was negligible. Despite gaining FDA approval, no patients received Beqvez post-approval, reflecting broader challenges in commercializing hemophilia gene therapies, a pattern seen with other approved products in the same category. Regulatory approval and real-world access are not the same thing, and the gap between them, driven by pricing, insurance coverage, and manufacturing complexity, is one of the defining challenges in this field.

For patients with rare genetic diseases, the stakes are intensely personal. As much as 80% of rare disease is caused by single-gene defects, making these conditions natural candidates for gene therapy intervention. The vast majority of newly approved cell and gene therapies carry Orphan Drug designations, reflecting their focus on conditions with small patient populations and historically few treatment options.

Conclusion: Two approaches, one goal, and a future still being written

Gene therapy and cell therapy represent a genuine paradigm shift in how medicine addresses disease, moving from symptom management toward targeting the biological mechanisms of illness itself. Gene therapy corrects the instruction code; cell therapy delivers new functional components. Where they converge, as in CAR-T and CRISPR-modified cell treatments, the results are among the most exciting in modern clinical science.

The honest picture is one of enormous promise tempered by real-world complexity. Access, cost, long-term safety, and manufacturing scale remain unsolved problems. But the pace of progress, measured in approvals, trials, and patients treated, is unmistakably accelerating. For patients living with rare genetic diseases or treatment-resistant cancers, these are not abstract developments. They are, for a growing number of people, the difference between having a treatment option and having none.

Frequently Asked Questions (FAQ)

What is the main difference between gene therapy and cell therapy?

Gene therapy intervenes at the DNA level, correcting, replacing, or silencing faulty genes inside existing cells. Cell therapy introduces living cells into the body to repair, replace, or regulate biological function. Some advanced treatments, particularly CAR-T therapies, combine both approaches by genetically modifying cells outside the body before reinfusing them.

Are gene therapies and cell therapies approved and available now?

Yes. Multiple therapies in both categories have received regulatory approval from the FDA and EMA. Approved treatments currently cover conditions including sickle cell disease, certain blood cancers, inherited blindness, spinal muscular atrophy, and epidermolysis bullosa, among others. Availability varies significantly by country, healthcare system, and insurance coverage.

Are these therapies safe?

The safety profile varies by therapy and condition. Most approved treatments have demonstrated acceptable safety in clinical trials, but risks include immune reactions, potential off-target genetic changes, and, in the case of CAR-T, serious inflammatory reactions such as cytokine release syndrome. The FDA requires up to fifteen years of post-treatment follow-up for gene therapies to monitor long-term effects.

Why do gene and cell therapies cost so much?

The manufacturing process is extraordinarily complex, many therapies are produced individually for each patient using their own cells. Clinical development is lengthy and expensive, and patient populations are often small. These factors combine to produce price points that most healthcare systems are still working out how to manage equitably.

Who is a candidate for gene or cell therapy?

Eligibility depends entirely on the specific therapy and condition. Most currently approved treatments target rare genetic disorders or specific cancer types that have not responded to conventional treatment. A specialist in haematology, oncology, or rare disease genetics is best placed to assess individual candidacy.

Last updated

April 7, 2026

Medically reviewed by:

Sources

Read also

  • Subscribe to our health letter

Menu